TheStreet questioned study results released this morning by Oncolytics Biotech Inc. (Nasdaq: ONCY) for its head and neck cancer treatment Reolysin sending the stock price plummeting 60 cents to close at $1.92.
TheStreet Questioned Oncolytics Biotech’s Study Results
November 21, 2013 at 09:38 AM EST
